Dulaglutide as a Substitute for Long-Acting Insulin in a Basal-Bolus Regimen?

Blood glucose was controlled a little better but at the cost of more adverse events.

When type 2 diabetes is difficult to control, clinicians often resort to basal-bolus insulin regimens. Could the long-acting basal insulin in such a regimen be replaced by a long-acting glucagon-like peptide-1 (GLP-1) agonist, perhaps conferring lower risk for hypoglycemia?

Dulaglutide (Trulicity) is a GLP-1 agonist that was approved by the FDA in 2014 for once-weekly injection. In a manufacturer-conducted study, researchers randomized 884 adults with glycosylated hemoglobin (HbA_1c) levels ≥7.0%, despite fixed insulin doses once or twice daily, to receive weekly dulaglutide (0.75 or 1.5 mg) or daily bedtime insulin glargine (Lantus). All patients received thrice-daily prandial insulin lispro (Humalog). Participants were allowed to take metfo…

Reviewing Author

Bruce Soloway, MD

Disclosures

Editorial BoardsNew RoAR News (http://www.newroarnews.org)

Bruce Soloway, MD

Disclosures

Editorial BoardsNew RoAR News (http://www.newroarnews.org)

Dulaglutide as a Substitute for Long-Acting Insulin in a Basal-Bolus Regimen?

Topics

Reviewing Author